Mainz BioMed N.V. · ISIN: NL0015000LC2 · EQS - Company News

Mainz Biomed Announces Stock Split

Mainz Biomed Announces Stock Split BERKELEY, US and MAINZ, Germany – November 29, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a 1-for-40 reverse stock split of its issued and outstanding shares.  The reverse stock split was authorized by the Board of Directors of the Company pursuant to shareholder approval granted at its Extraordinary Shareholders Meeting on Nove...

FWB:4TO Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Mainz BioMed N.V.

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
29 November 2024 02:45PM
Mainz Biomed Announces Stock Split
NL0015000LC2
Mainz Biomed Announces Stock Split BERKELEY, US and MAINZ, Germany – November 29, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a 1-for-40 reverse stock split of its issued and outstanding shares.  The reverse stock sp...
Mainz BioMed N.V.
About the publication
12 November 2024 03:00PM
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
NL0015000LC2
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets BERKELEY, US and MAINZ, Germany – November 12, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...
Mainz BioMed N.V.
About the publication
21 October 2024 02:01PM
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
NL0015000LC2
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8...
Mainz BioMed N.V.
About the publication
08 October 2024 02:00PM
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
NL0015000LC2
  Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-Baden   BERKELEY, US and MAINZ, Germany – October 8, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnost...
Mainz BioMed N.V.
About the publication
01 October 2024 02:01PM
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
NL0015000LC2
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 BERKELEY, US and MAINZ, Germany – October 1, 2024 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today released a statement to sharehold...
Mainz BioMed N.V.
About the publication
18 September 2024 02:01PM
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
NL0015000LC2
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection   BERKELEY, US and MAINZ, Germany – September 18, 2024 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”...
Mainz BioMed N.V.
About the publication
18 September 2024 02:01PM
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
NL0015000LC2
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection   BERKELEY, US and MAINZ, Germany – September 18, 2024 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”...
Mainz BioMed N.V.
About the publication
04 September 2024 10:01AM
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
NL0015000LC2
 Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First Analysis  BERKELEY, US and MAINZ, G...
Mainz BioMed N.V.
About the publication
25 July 2024 02:01PM
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
NL0015000LC2
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience BERKELEY, US – MAINZ, Germany – July 25, 2024 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in early detection of cancer, today announced significant improvements to its ColoAlert prod...
Mainz BioMed N.V.
About the publication
09 July 2024 09:01AM
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test  
NL0015000LC2
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal registration study ReconAAsense A recent clini...
Mainz BioMed N.V.
About the publication
02 July 2024 02:01PM
Mainz Biomed Provides Half Year 2024 Corporate Update
NL0015000LC2
Mainz Biomed Provides Half Year 2024 Corporate Update Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study BERKELEY, US – MAINZ, Germany – July 2, 2024 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments ...
Mainz BioMed N.V.
About the publication
03 June 2024 02:01PM
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
NL0015000LC2
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia  Results from pooled study represents the third consecutive confirmation ...
Mainz BioMed N.V.
About the publication
03 June 2024 02:01PM
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
NL0015000LC2
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia  Results from pooled study represents the third consecutive confirmation ...
Mainz BioMed N.V.
About the publication
28 May 2024 02:01PM
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
NL0015000LC2
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects including previously unexamined and unreported samples from the pooled ColoF...
Mainz BioMed N.V.
About the publication
07 May 2024 02:01PM
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
NL0015000LC2
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82% BERKELEY, US – MAINZ, Germany – May 7, 2024 — Mainz Biomed N.V. ...
Mainz BioMed N.V.
About the publication
07 May 2024 02:01PM
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
NL0015000LC2
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82% BERKELEY, US – MAINZ, Germany – May 7, 2024 — Mainz Biomed N.V. ...
Mainz BioMed N.V.
About the publication
25 April 2024 03:29PM
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next-Gen CRC Test
NL0015000LC2
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-c...
Mainz BioMed N.V.
About the publication
09 April 2024 02:01PM
Mainz Biomed Reports Full Year 2023 Financial Results
NL0015000LC2
Mainz Biomed Reports Full Year 2023 Financial Results ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 Million BERKELEY, US – MAINZ, Germany – April 9, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions ...
Mainz BioMed N.V.
About the publication
19 March 2024 01:01PM
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
NL0015000LC2
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment BERKELEY, US – MAINZ, Germany – March 19th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, will be organizing the HALLO DOC! event, informing about...
Mainz BioMed N.V.
About the publication
18 March 2024 01:01PM
Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
NL0015000LC2
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options BERKELEY, US – MAINZ, Germany – March 18th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host a...
Mainz BioMed N.V.
About the publication
12 March 2024 02:01PM
Leading the Way in Evidence-Based Cancer Screening Innovations
NL0015000LC2
 Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations BERKELEY, US – MAINZ, Germany – March 12th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is proud to announce its upcoming...
Mainz BioMed N.V.
About the publication
05 March 2024 02:01PM
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
NL0015000LC2
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic  Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaboration   Mainz Biomed’s Pivotal FDA PMA clini...
Mainz BioMed N.V.
About the publication
27 February 2024 02:01PM
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
NL0015000LC2
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community BERKELEY, US – MAINZ, Germany – February 27th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is proud to annou...
Mainz BioMed N.V.
About the publication
22 February 2024 02:01PM
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
NL0015000LC2
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert® BERKELEY, US – MAINZ, Germany – February 22nd, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is pleased to announce a distribution partnership with Praxisdienst...
Mainz BioMed N.V.
About the publication
21 February 2024 02:01PM
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
NL0015000LC2
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy Partnership Brings Pioneering Approach to Incorporating Advanced Colorectal Cancer Detection Into Country’s Healthcare System BERKELEY, US – MAINZ, Germany – February 21st, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Compan...
Mainz BioMed N.V.
About the publication
06 February 2024 02:01PM
MAINZ BIOMED ESTABLISHES PHYSICIAN-LED LABORATORY EXPANDING SERVICE OFFERING FOR PRIVATELY INSURED PATIENTS IN GERMANY
NL0015000LC2
MAINZ BIOMED ESTABLISHES PHYSICIAN-LED LABORATORY EXPANDING SERVICE OFFERING FOR PRIVATELY INSURED PATIENTS IN GERMANY  Company opens own physician-led laboratory, ‘European Oncology Lab’ (EOL), thereby offering ColoAlert® as a laboratory medical service directly to physicians and patients. BERKELEY, US – MAINZ, Germany – February 6, 2024 — Mainz...
Mainz BioMed N.V.
About the publication
11 January 2024 02:01PM
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
NL0015000LC2
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium BERKELEY, US – MAINZ, Germany – January 11, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in early cancer detection, re-affirms its collaboration with TestDNA at the upcoming 1...
Mainz BioMed N.V.
About the publication
09 January 2024 02:01PM
Mainz Biomed Provides Year-End Corporate Review 2023
NL0015000LC2
Mainz Biomed Provides Year-End Corporate Review 2023 European Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Colorectal Cancer and Advanced Adenoma exceeding competition   ReconAAsense designed to evaluate gold standard at home colorectal cancer screening test and is on track to commence enr...
Mainz BioMed N.V.
About the publication
19 December 2023 02:01PM
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
NL0015000LC2
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and Crimmitschau, in Q1 2024. BERKELE...
Mainz BioMed N.V.
About the publication
12 December 2023 02:01PM
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
NL0015000LC2
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland BERKELEY, US – MAINZ, Germany – DECEMBER 12, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its active participation alongside Po...
Mainz BioMed N.V.
About the publication
05 December 2023 03:01PM
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
NL0015000LC2
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers Groundbreaking Results Demonstrate Sensitivity for Colorectal Cancer of 97% with Specificity of 97% and Advanced Adenoma Sensitivity of 82%   Results Exceed those from the Company’s European ColoFuture Clinical Study of the Same Design ...
Mainz BioMed N.V.
About the publication
29 November 2023 02:01PM
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
NL0015000LC2
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast BERKELEY, US – MAINZ, Germany – NOVEMBER 29, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that its presenta...
Mainz BioMed N.V.
About the publication
20 November 2023 02:01PM
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference 
NL0015000LC2
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference   BERKELEY, US – MAINZ, Germany – November 20, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that Guido Baechler, Chief Executive Officer and Bil...
Mainz BioMed N.V.
About the publication
16 November 2023 02:01PM
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
NL0015000LC2
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update ColoAlert® Revenue Increases 102% Year Over Year for the Nine Months Ended September 30, 2023  ColoFuture Study Reported Groundbreaking Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 8...
Mainz BioMed N.V.
About the publication
15 November 2023 03:01PM
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
NL0015000LC2
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering BERKELEY, US – MAINZ, Germany – NOVEMBER 15, 2023 — Mainz Biomed N.V. (Nasdaq: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the closing of its previously announced registered d...
Mainz BioMed N.V.
About the publication
13 November 2023 03:00PM
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
NL0015000LC2
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering BERKELEY, US – MAINZ, Germany – NOVEMBER 13, 2023 — Mainz Biomed N.V. (Nasdaq: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has entered into a securities purchase agree...
Mainz BioMed N.V.
About the publication
09 November 2023 02:01PM
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
NL0015000LC2
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test Collaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing  BERKELEY, US – MAINZ, Germany – NOVEMBER 9, 2023 — Mainz Biomed NV (NASDAQ:MYNZ...
Mainz BioMed N.V.
About the publication
07 November 2023 02:01PM
Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
NL0015000LC2
 Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA  BERKELEY, US – MAINZ, Germany – NOVEMBER 7, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that VP Commercial Operations, Tarrin Khairi-Ta...
Mainz BioMed N.V.
About the publication
31 October 2023 01:01PM
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
NL0015000LC2
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper Almost half of Zöller-KipperGmbH’s employees in Germany participated in the screening program so far using ColoAlert®, Mainz Biomed’s user-friendly, at-home colorectal cancer (CRC) screening test. BERKELEY, US – MAINZ, Germany – Octo...
Mainz BioMed N.V.
About the publication
26 October 2023 02:01PM
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
NL0015000LC2
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations Former Natera Manager will oversee all aspects of sales and support in EMEA, ensuring the continued commercialization of ColoAlert® across the region BERKELEY, US – MAINZ, Germany – October 26, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a mole...
Mainz BioMed N.V.
About the publication
18 October 2023 02:01PM
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
NL0015000LC2
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study Results indicate a substantial and meaningful enhancement in the effectiveness of non-invasive colorectal cancer (CRC) screening, particularly for the detection of advanced adenomas, a precursor to CRC Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensit...
Mainz BioMed N.V.
About the publication
11 October 2023 02:01PM
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
NL0015000LC2
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark Mainz Biomed team members will be available throughout the event at the Company’s booth located in Hall C, Stand C3-92 BERKELEY, US – MAINZ, Germany – October 11, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leading molecular genetics diagnost...
Mainz BioMed N.V.
About the publication
05 October 2023 02:01PM
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
NL0015000LC2
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit  BERKELEY, US – MAINZ, Germany – October 5, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Bill Caragol, Chief Financial Officer, will attend the Jones...
Mainz BioMed N.V.
About the publication
04 October 2023 02:01PM
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
NL0015000LC2
 Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania Strategic Collaboration Elevates Early Cancer Detection, Bringing State-of-the-Art Diagnostic Capabilities to Romanian Population BERKELEY, US – MAINZ, Germany – OCTOBER 4, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagn...
Mainz BioMed N.V.
About the publication
27 September 2023 02:01PM
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
NL0015000LC2
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma sensitivity of 81%   Pulsus Group’s 4th International Conference on Gastroent...
Mainz BioMed N.V.
About the publication
20 September 2023 09:01AM
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
NL0015000LC2
 Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference  BERKELEY, US – MAINZ, Germany – September 20, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Guido Baechler, Chief Executive Officer, ...
Mainz BioMed N.V.
About the publication
13 September 2023 09:01AM
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advance
NL0015000LC2
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%   Multiple novel mRNA biomarkers identified for potential integration into pivotal FDA PMA clinical trial (ReconAAsense)...
Mainz BioMed N.V.
About the publication
05 September 2023 09:01AM
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
NL0015000LC2
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market BERKELEY, US – MAINZ, Germany – September 5, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a strateg...
Mainz BioMed N.V.
About the publication
More Mainz BioMed N.V. related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN